News

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

With markets at elevated multiples in May 2026, low share prices can mislead investors into thinking quality is out of reach. Stocks trading below $30 with strong balance sheets offer income, deleveraging stories, or growth at valuations that build in a margin of safety. Here are five stocks trading under $30 that pair solid books ... The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks under $30 often get dismissed as broken or speculative, but a handful of large, cash-generative businesses currently trade in that zone with the ... Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

These stocks could look like steals in a few years.

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing

With an annual dividend yield of 6.68%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Dividend Stocks with 5%+ Yields and Growing Cash Flows. On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 from $25. It reiterated an Underperform rating on the shares following what the […]

The Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) and the Fundstrat Granny Shots US Large Cap ETF (NYSEARCA:GRNY) sit on opposite ends of how quality gets defined in a large-cap portfolio. COWZ ranks the Russell 1000 by free cash flow yield and takes the top 100 names, a rules-based screen with no human override. GRNY ... GRNY Beat COWZ by 11 Points This Year. Oil Prices and Interest Rates Will Decide Who Wins Next

Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI to adolescents with hemophilia A or B and inhibitors. The decision opens access to a new patient group within the EU hemophilia market for this rare disease therapy. The expanded label highlights bleed protection and a simplified administration regimen for a hard to treat population. For investors watching NYSE:PFE, this update is part of Pfizer's broader push in rare diseases, an area where specialized treatments...

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.

Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year.

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launched and acquired products, particularly in oncology and migraine therapies. CEO Albert Bourla credited a 22% increase in revenues from new products and acquisitions, highlighting the success of the Seagen integration and robust demand for Nurtec. Management also pointed to positive developments in legal settlements, which have improved clari

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results. The company reported […]

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

Pfizer Inc. (NYSE:PFE) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. A caller inquired if they should hold, sell, or buy more. In response, Cramer said: Pfizer does not have any earnings momentum. You’re just buying it on that dividend […]

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers.

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. Below are the publicly traded category leaders in each. Each is a well-positioned standalone business ... Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Lead

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Meta ramps AI infrastructure spending as upgraded recommendations and advertiser tools boost engagement and ad efficiency.

Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and...

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

Meta ramps up AI infrastructure and ad tools as Pfizer rebounds and Salesforce expands AI offerings amid macro pressures.